UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~WASHINGTON~~Washington, DCD.C. 20549

FORM 8-K

CURRENT REPORT ~~PURSUANT~~

TOPURSUANT TO SECTION 13 OR 15(Dd) OF ~~THE~~

~~SECURITIES~~THE SECURITIES EXCHANGE ACT OF 1934

Date of Report ~~report~~ (Date of earliest event reported): ~~June~~January 1720, ~~2008~~ 2009

~~SFH~~PROTECH 1GLOBAL ~~ACQUISITION~~HOLDINGS CORP.

(Exact ~~Name~~name of ~~Registrant~~registrant as ~~Specified~~specified in ~~Its~~its ~~Charter~~charter)

Delaware

Delaware	000-52643	20-5941535
(State or Other Jurisdiction	(Commission File	(I.R.S. Employer
of Incorporation)	Number)	Identification Number)

~~(State~~3363 NE or163rd Street, ~~Other~~Suite ~~Jurisdiction~~706, ofNorth ~~Incorporation)~~Miami Beach, Florida 33160

000-52643		20-5941535
(Commission File Number)		(IRS Employer Identification No.)
3363 NE 163rd Street Suite 705
North Miami Beach, Florida
(Address of Principal Executive Offices)

(Address of principal executive offices) (zip code)

(786) ~~629~~923-~~0334~~0512

(Registrant’'s ~~Telephone~~telephone ~~Number~~number, ~~Including~~including ~~Area~~area ~~Code~~code)

Copies to:

Andrea Cataneo, Esq.

Sichenzia Ross Friedman Ference LLP

61 Broadway

New York, New York 10006

Phone: (212) 930-9700

Fax: (212) 930-9725

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Forward~~Item ~~Looking~~4.01 Change ~~Statements~~in Registrant’s Certifying Accountant.

~~Certain statements~~On ~~included~~January in20, ~~this~~2009, ~~Form~~the ~~8-k~~board ~~regarding~~of directors ~~SFH~~of 1Protech ~~Acquisition~~Global Holdings Corp. ( the “Company”) ~~that~~dismissed ~~are~~Sherb ~~not historical facts are forward-looking statements,~~& ~~including the information provided with respect to the future business operations and anticipated operations of the Company~~Co. ~~These forward-looking statements are based on current expectations~~, ~~estimates,~~LLP ~~assumptions~~(“Sherb”) ~~and beliefs of management, and words such~~ as "expects," "anticipates," "intends," "plans," "believes," "estimates" and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve risks and uncertainties, including, but not limited to, the ~~success of our~~Company’s ~~current~~independent orregistered ~~proposed~~public ~~business activities. Accordingly, actual results may~~accounting ~~differ~~firm.

~~Item~~During 1the fiscal year ended December 31, 2007, and any subsequent period through January 20, 2009, (i) there were no disagreements between the Company and Sherb on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure which, if not resolved to the satisfaction of Sherb would have caused Sherb to make reference to the matter in its reports on the Company's financial statements, and (ii) Sherb’s reports on the Company's financial statements did not contain an adverse opinion or disclaimer of opinion, and was not modified as to uncertainty, audit scope or accounting principles.01 ~~Entry~~During ~~into~~the fiscal year ended December 31, 2007 and through January 20, 2009, there were no reportable events as the term described in Item 304(a)(1)(iv) ~~Material~~of ~~Definitive~~Regulation ~~Agreement~~S-K.

On ~~June 17~~January 20, ~~2008~~2009, the Company ~~entered~~provided ~~into~~Sherb ~~an agreement~~ with ~~the~~a ~~shareholders~~copy of ~~Protech~~the disclosures it ~~Biosystems~~is ~~Pvt.~~making ~~Ltd.~~in ~~(“Protech”)~~response to ~~acquire~~Item ~~all~~4.01 ofon ~~the~~this ~~issued~~Form 8-K, and ~~outstanding shares~~has ofrequested ~~common~~that Sherb ~~stock~~furnish ofit ~~Protech~~with ina ~~exchange~~letter ~~for~~addressed ~~6.1~~to ~~million~~the ~~shares~~Securities ofand ~~the~~Exchange ~~Company’s~~Commission ~~common~~stating ~~stock.~~whether ~~Protech~~it isagrees awith ~~company~~the ~~incorporated~~above ~~in India~~statements. ~~Closing~~A copy of ~~the~~ ~~transaction will be subject to certain conditions precedent including but~~the ~~not~~letter, ~~limited~~dated toJanuary ~~delivery~~22, of2009, ~~audited~~is ~~financial~~filed ~~statements~~as inExhibit ~~conformity with U~~16.~~S. GAAP~~1 (of which ~~draft~~is ~~copies~~incorporated by ~~have~~reference ~~been provided~~herein) ~~and~~to ~~the~~this ~~approval~~Current ofReport ~~the appropriate~~on ~~regulatory~~Form ~~body in India~~8-K.

~~Upon~~On ~~closing~~January of20, 2009, the ~~transaction,~~Company itengaged isBansal ~~contemplated~~& ~~that~~Co. (“Bansal”) as its independent registered public accounting firm for the ~~current~~Company’s ~~management~~fiscal year ~~of Protech~~ended ~~will~~December ~~become~~31, ~~officers~~2008. ~~and~~The ~~directors~~change ofin the Company.’s independent registered public accounting firm was approved by the Company’s Board of Directors on January 20, 2009.

~~PROTECH:~~During the year ended December 31, 2007 and any subsequent period through January 20, 2009, the Company did not consult with Bansal regarding either (i) the application of accounting principles to a specific completed or contemplated transaction, or the type of audit opinion that might be rendered on the Company’s financial statements or (ii) any matter that was either the subject of a disagreement or event identified in response to (a)(1)(iv) of Item 304 of Regulation S-K.

~~Protech~~Item ~~was incorporated in 1998 by Dr~~9.01 ~~Sanjiw~~Financial ~~Kumar~~Statements Singh. Also in 1998, Protech started its commercial operations in New Dehli, India for the manufacture of pharmaceutical formulations.The company started manufacturing the pharmaceutical products on loan license in India and ~~started exports of the same to Russia and other countries~~Exhibits. ~~Its mission is to develop and distribute generic drug products both in India and throughout the world.~~

In March 2004, Protech acquired its own manufacturing plant and started the commercial production thereof in 2005. Protech has the facilities and ability to manufacture injections, tablets, capsules, liquid syrups and ointments with its modern facilities. Protech operates in twelve states in India for its domestic sales and exports to Russia & CIS countries. Protech employs approximately 600 persons and maintains a team of 100 representatives for its overseas operations. Protech delivers about 30 products in the domestic market and about 15 products for exports.

Exhibit Number		Description

16.1		Letter re Change in Certifying Accountant

Protech maintains a research and development center, which has made significant breakthroughs in development of various active pharmacological ingredients and research is continuously in progress for development and commercialization of more products. Many of the other products under development in research and development will in the future not be subject to patent protection in Europe and the United States. This should increase export sales of Protech’s generic products over the next few years. To capitalize on this opportunity, it is essential that Protech establish and maintain a state-of-the-art multi-product drug plant conforming to international standards. With this in view, Protech has set-up the facility to meet the production requirements and meet the ever-growing demand for such kind of products in the international markets.

Quality Assurance.

Protech is in the business of manufacturing finished dosage formulations. It is Protech’s objective to meet the needs and requirements of its customers by offering consistent quality products and services at all times. Protech is committed to improve the quality of its products and services through continuous up-gradation of technology, and continuous training and development of personnel to effectively adapt to newer technologies and higher standards of service. Protech’s goal is to insure that its customers throughout the world derive the full satisfaction of using its products and services. Protech is committed to follow and comply with quality management systems as proposed by Indian and International regulatory authorities.

Doing Business in India

Introduction

India - with its consistent growth performance and abundant highly skilled manpower provides enormous opportunities for investments. India is the largest democracy and tenth largest economy in the world. India is the fourth largest economy in the world in terms of purchasing power parity.

India has a federal system of Government with clear demarcation of powers between the Central Government and the State Governments.

India provides a liberal, attractive, and investor friendly investment climate.

India encourages foreign direct investment (FDI). .

India has liberalized and simplified foreign exchange controls.

Indian economy has been growing at an average growth rate of about 8.6% per year over the last three years.

Management

It is expected that on closing of the transaction, Sanjiw Kumar Singh, the current chief executive officer of Protech will become our chief executive officer. Mr. Singh has since 1996 been involved with pharmaceutical sales, distribution and manufacturing in both India and Russia.

Exhibits:

10.1 Share Exchange Agreement between SFH I Acquisition Corp and the Shareholders of Protech Biosystems Pvt Ltd.

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the ~~Registrant~~registrant has duly caused this report to be signed on its behalf by the undersigned ~~hereunto~~ hereunto duly authorized.

Date: June 19, 2008

	PROTECH GLOBAL HOLDINGS CORP.

Dated: January 22, 2009	By /s/ Ajay Gupta
	Name: Ajay Gupta
	Title: Chief Financial Officer

	SFH 1 Acquisition Corp.
	By:	/s/ Armen Karapetyan
		Armen Karapetyan
		President

Filing Compare · Protech Global Holdings Corp.